Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Core Insights - Acrivon Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing precision oncology medicines using its proprietary platform, Acrivon Predictive Precision Proteomics (AP3) [1][3] - The company has granted an equity award in the form of stock options to an employee as part of its 2023 Inducement Plan, with options to purchase 99,300 shares of common stock [2] Company Overview - Acrivon utilizes the AP3 platform to identify patients whose tumors are predicted to be sensitive to specific medicines, optimizing drug design and identifying rational drug combinations [3] - The lead candidate, ACR-368, is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a potentially registrational Phase 2 trial for multiple tumor types [3] - ACR-368 has received Fast Track designation from the FDA for use as monotherapy in patients with platinum-resistant ovarian or endometrial cancer [3] - The ACR-368 OncoSignature test, which is still awaiting regulatory approval, has been evaluated in preclinical studies and has received Breakthrough Device designation from the FDA [3] - Acrivon is also developing additional preclinical stage programs, including ACR-2316, a selective dual WEE1/PKMYT1 inhibitor [3]